| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 11/5/267:00 AM | -$0.18 | $0.03GAAP | +117% | +109% | $36.2M | $54.4M | +50.3% | +326% | |
| Q2 '26 | 8/6/267:00 AM | -$0.34 | -$0.43GAAP | -26.5% | -187% | $15.4M | $9.0M | -41.9% | -61% | |
| Q1 '26 | 5/7/267:00 AM | -$0.36 | -$0.45GAAP | -25.0% | -179% | $13.4M | $4.2M | ⚠ Check | ⚠ Check | |
| Q4 '25 | 3/17/267:00 AM | -$0.39 | -$0.55GAAP | -41.0% | -339% | $13.4M | $2.8M | ⚠ Check | ⚠ Check | |
| Q3 '25 | 11/6/257:00 AM | -$0.37 | -$0.33GAAP | +10.8% | -14% | $7.5M | $12.8M | +69.5% | +39% | |
| Q2 '25 | 8/7/257:00 AM | -$0.34 | -$0.15GAAP | +55.9% | +65% | $8.7M | $23.2M | ⚠ Check | +394% | |
| Q1 '25 | 5/8/257:00 AM | -$0.32 | $0.57GAAP | +278% | +208% | $13.6M | $84.9M | ⚠ Check | ⚠ Check |
⚠ Potential error in calculation, check manually. The two revenue figures may be in different units or currencies.
GAAP = diluted EPS as filed with the SEC.